• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DNDi & Cipla Advance Development of Paediatric 4-in-1 ARVs to Fulfill New WHO Guidelines

Kuala Lumpur, Malaysia — 30 Jun 2013
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Immediate, Expanded, and Improved Treatments Needed for Infants and Toddlers with HIV
The World Health Organization’s new HIV treatment guidelines, released today at the 2013 International AIDS Society (IAS) Conference, include new antiretroviral (ARV) therapy (ART) recommendations for HIV-infected children, and will mean that more children will be on better treatments. The Drugs for Neglected Diseases initiative (DNDi) applauds the new guidelines and, with Cipla Ltd. and other partners, is expediting the development of urgently needed 4-in-1 ARVs adapted for babies and toddlers with HIV, to be delivered by 2015.

The new 2013 WHO Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection were released today at the 7thIAS Conference on HIV Pathogenesis, Treatment and Prevention. The updated guidelines call for immediate ART for all HIV-infected children under five years of age, regardless of clinical or immunological status, which will greatly broaden the paediatric HIV patient population on treatment and thus increase demand. Importantly, the guidelines also recommend the use of potent protease inhibitor-based first-line ARV regimens, ideally in a fixed-dose combination (FDC), for all children under three years old.

‘The new international guidelines call for getting many more young kids with HIV on the best treatment with no delay’, said Dr Bernard Pécoul, Executive Director of DNDi. ‘‘We are reassured that the pediatric ARV formulation we are striving to deliver to babies and toddlers with HIV is completely aligned with the WHO’s new recommendations.’

Welcoming the new international HIV guidelines, Dr Jaideep A Gogtay, Chief Medical Officer of Cipla said, ‘Cipla reinforces its commitment towards HIV/AIDS and will continue to develop novel and child-friendly formulations to ensure wider access of ARV drugs to HIV-infected children.’

An estimated 3.3 millionchildren (<15 years old) live with HIV/AIDS, but only 28% of those in need of treatment are receiving it, compared with 54% of adults. Without treatment, half of all HIV-positive children will die before the age of two, and 80% will die before they turn five years old.

DNDi entered the field of paediatric HIV in 2011 due to the critical unmet need of an appropriate ARV formulation for infants and young children. Current formulations of protease inhibitors for children too young to swallow tablets are in an alcohol-based liquid form. These formulations taste terrible, are difficult to store and transport, and require refrigeration, which is a hindrance in many developing countries. Additionally, administering the correct dose of medicine is challenging since it involves measuring precise amounts of various liquid formulations, which risks errors in dosing. Undesirable interactions with drugs for tuberculosis, the most common co-infection with HIV, pose further challenges.

To fulfill the need for better paediatric formulations, DNDi is partnering with the Indian drug manufacturer Cipla Ltd. to develop two 4-in-1 ARV FDCs designed specifically for children under three years of age, or until they are able to swallow tablets. This new formulation comprises tiny granules, which fit into a capsule that can be opened to spread the medicine onto soft food or be mixed with milk. The ARVs are ‘taste-masked’, require no refrigeration, and are easy to dose according to the child’s weight.

‘Since its creation in 2006, UNITAID has been addressing paediatric HIV by creating the market for child-friendly antiretroviral treatments as previously there was no incentive for pharmaceutical companies to invest in developing these medicines and so none existed’, said Philippe Douste-Blazy, Chair of the Board of UNITAID. ‘The international community must continue to commit to developing the best possible treatments to avoid childhood HIV becoming a neglected disease. UNITAID’s investment in this project with DNDi is already a vital contribution.’

The two ‘4-in-1’ combinations contain lopinavir/ritonavir + zidovudine + lamivudine (LPV/r/AZT/3TC) and lopinavir/ritonavir + abacavir + lamivudine (LPV/r/ABC/3TC), respectively. An additional formulation of ritonavir granules is being developed for babies and young children who require treatment for both HIV and tuberculosis. The goal is to make these new FDCs available by 2015, by working closely with health professionals in the field and research organizations in the most affected countries.

‘We are racing against the clock to ensure rapid delivery of a new 4-in-1 ARV medicine for young children,’ said Dr Marc Lallemant, Head of DNDi’s Paediatric HIV Programme. ‘Yet getting from the recommendations to actual implementation and treatment access will require the full support of donors, international and national regulatory authorities, national HIV programmes, civil society, and people living with HIV themselves to make this a reality for HIV-infected children.’

DNDi’s paediatric HIV drug development programme is supported financially by UNITAID, the French Development Agency (AFD), and Médecins Sans Frontières/Doctors Without Borders (MSF).

Read DNDi’s 2013 pediatric HIV overview, “Accelerating the Development and Delivery of Antiretroviral Treatment for Children with HIV/AIDS” [pdf]

About Paediatric HIV/AIDS
According to UNAIDS (2011), an estimated 3.3 million children under the age of 15 years are living with HIV/AIDS, 3.1 million of whom (94%) live in sub-Saharan Africa. Each day, more than 900 children are newly infected with HIV and 600 die from AIDS-related complications. Only 355,000 HIV-positive children have access to antiretroviral therapy (ART), representing just 28% of those in urgent clinical need. Without treatment, one-third of children born with HIV will die before their first birthday, 50% will die before they turn two, and 80% will die before they are five years old.

About the Drugs for Neglected Diseases initiative (DNDi)
DNDi is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular human African trypanosomiasis, Chagas disease, leishmaniasis, filaria, and paediatric HIV. DNDi was established in 2003 by Médecins Sans Frontières/Doctors Without Borders (MSF), Oswaldo Cruz Foundation of Brazil, Indian Council for Medical Research, Kenya Medical Research Institute, Ministry of Health of Malaysia, and Institut Pasteur of France. The WHO Special Programme for Research and Training in Tropical Diseases (WHO-TDR) serves as a permanent observer. Since 2003, DNDi has delivered six treatments for neglected patients: two fixed-dose drug combinations for malaria (ASAQ and ASMQ); nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness; sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa; a set of combination therapies for visceral leishmaniasis in Asia; and a paediatric formulation of benznidazole for Chagas disease.
www.dndi.org

About Cipla
Cipla laid the foundation for the Indian pharmaceutical industry in 1935, with the vision to make India self-reliant in healthcare. Over the years, Cipla has emerged as one of the most respected names not just in India but worldwide. Its state-of-the-art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. The company has over 34 manufacturing facilities across India, and manufactures 2,000+ products in 65 therapeutic categories. With a turnover of over US $ 1.5 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices.
www.cipla.com

Media contacts (on site at IAS):
Peng Lin Wong: Tel: +60 12 425 5020 / email: plwong@dndi.org
Oliver Yun: Tel: +1-646-266-5216 / email: oyun@dndi.org

Funding Paediatric HIV

Read, watch, share

Loading...
Mark Sullivan
News
2 Oct 2023

Mark Sullivan joins the DNDi Scientific Advisory Committee

Centre of Excellence in India
News
14 Sep 2023

DNDi’s Centres of Excellence: Towards the sustainable elimination of visceral leishmaniasis in India

Delali Attip
Press releases
6 Sep 2023

Biotech leader Delali Attiogbe Attipoe joins DNDi as North America Director

Viewpoints
5 Sep 2023

Africa should bolster research into climate-sensitive diseases

Context
Prof. Sam Kariuki, DNDi Eastern Africa Director and Leonard Ithau, Rotary International District 9212 District Governor shaking hands
News
29 Aug 2023

DNDi and Rotary collaborate to prevent and treat diseases affecting neglected communities in Eastern Africa

Mother and child in a hospital
Viewpoints
24 Aug 2023

A drug development model for the diseases the world forgot

Africa Arguments
Statements
21 Aug 2023

DNDi urges G20 to operationalize equity in response to major global health challenges and priorities

Man looking into a microscope
Press releases
31 Jul 2023

Certara and DNDi partnering to fast-track data submissions and accelerate drug approvals for neglected patients

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo